Literature DB >> 22739125

Acute pharmacologically induced shifts in serotonin availability abolish emotion-selective responses to negative face emotions in distinct brain networks.

Cheryl L Grady1, Hartwig R Siebner, Bettina Hornboll, Julian Macoveanu, Olaf B Paulson, Gitte M Knudsen.   

Abstract

Pharmacological manipulation of serotonin availability can alter the processing of facial expressions of emotion. Using a within-subject design, we measured the effect of serotonin on the brain's response to aversive face emotions with functional MRI while 20 participants judged the gender of neutral, fearful and angry faces. In three separate and counterbalanced sessions, participants received citalopram (CIT) to raise serotonin levels, underwent acute tryptophan depletion (ATD) to lower serotonin, or were studied without pharmacological challenge (Control). An analysis designed to identify distributed brain responses identified two brain networks with modulations of activity related to face emotion and serotonin level. The first network included the left amygdala, bilateral striatum, and fusiform gyri. During the Control session this network responded only to fearful faces; increasing serotonin decreased this response to fear, whereas reducing serotonin enhanced the response of this network to angry faces. The second network involved bilateral amygdala and ventrolateral prefrontal cortex, and these regions also showed increased activity to fear during the Control session. Both drug challenges enhanced the neural response of this set of regions to angry faces, relative to Control, and CIT also enhanced activity for neutral faces. The net effect of these changes in both networks was to abolish the selective response to fearful expressions. These results suggest that a normal level of serotonin is critical for maintaining a differentiated brain response to threatening face emotions. Lower serotonin leads to a broadening of a normally fear-specific response to anger, and higher levels reduce the differentiated brain response to aversive face emotions.
Copyright © 2012 Elsevier B.V. and ECNP. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22739125     DOI: 10.1016/j.euroneuro.2012.06.003

Source DB:  PubMed          Journal:  Eur Neuropsychopharmacol        ISSN: 0924-977X            Impact factor:   4.600


  10 in total

1.  Threat-related amygdala functional connectivity is associated with 5-HTTLPR genotype and neuroticism.

Authors:  Martin Korsbak Madsen; Brenda Mc Mahon; Sofie Bech Andersen; Hartwig Roman Siebner; Gitte Moos Knudsen; Patrick MacDonald Fisher
Journal:  Soc Cogn Affect Neurosci       Date:  2015-08-04       Impact factor: 3.436

Review 2.  Identifying predictors, moderators, and mediators of antidepressant response in major depressive disorder: neuroimaging approaches.

Authors:  Mary L Phillips; Henry W Chase; Yvette I Sheline; Amit Etkin; Jorge R C Almeida; Thilo Deckersbach; Madhukar H Trivedi
Journal:  Am J Psychiatry       Date:  2015-02-01       Impact factor: 18.112

3.  5-HTTLPR differentially predicts brain network responses to emotional faces.

Authors:  Patrick M Fisher; Cheryl L Grady; Martin K Madsen; Stephen C Strother; Gitte M Knudsen
Journal:  Hum Brain Mapp       Date:  2015-04-30       Impact factor: 5.038

4.  Fluctuations in [¹¹C]SB207145 PET binding associated with change in threat-related amygdala reactivity in humans.

Authors:  Patrick MacDonald Fisher; Mette Ewers Haahr; Christian Gaden Jensen; Vibe Gedsoe Frokjaer; Hartwig Roman Siebner; Gitte Moos Knudsen
Journal:  Neuropsychopharmacology       Date:  2015-01-06       Impact factor: 7.853

5.  Serotoninergic effects on judgments and social learning of trustworthiness.

Authors:  Arndis Simonsen; Jørgen Scheel-Krüger; Mads Jensen; Andreas Roepstorff; Arne Møller; Chris D Frith; Daniel Campbell-Meiklejohn
Journal:  Psychopharmacology (Berl)       Date:  2014-01-25       Impact factor: 4.530

Review 6.  The role of monoamine oxidase A in aggression: Current translational developments and future challenges.

Authors:  Sean C Godar; Paula J Fite; Kenneth M McFarlin; Marco Bortolato
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2016-01-09       Impact factor: 5.067

Review 7.  A neurocognitive model for understanding treatment action in depression.

Authors:  Matthew B Warren; Abbie Pringle; Catherine J Harmer
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2015-09-19       Impact factor: 6.237

8.  Acute serotonin 2A receptor blocking alters the processing of fearful faces in the orbitofrontal cortex and amygdala.

Authors:  Bettina Hornboll; Julian Macoveanu; James Rowe; Rebecca Elliott; Olaf B Paulson; Hartwig R Siebner; Gitte M Knudsen
Journal:  J Psychopharmacol       Date:  2013-07-02       Impact factor: 4.153

9.  Brain Networks Implicated in Seasonal Affective Disorder: A Neuroimaging PET Study of the Serotonin Transporter.

Authors:  Martin Nørgaard; Melanie Ganz; Claus Svarer; Patrick M Fisher; Nathan W Churchill; Vincent Beliveau; Cheryl Grady; Stephen C Strother; Gitte M Knudsen
Journal:  Front Neurosci       Date:  2017-11-03       Impact factor: 4.677

10.  Neuroticism predicts the impact of serotonin challenges on fear processing in subgenual anterior cingulate cortex.

Authors:  Bettina Hornboll; Julian Macoveanu; Ayna Nejad; James Rowe; Rebecca Elliott; Gitte M Knudsen; Hartwig R Siebner; Olaf B Paulson
Journal:  Sci Rep       Date:  2018-12-17       Impact factor: 4.379

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.